19 completed. 19 Phase 2, 5 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 19 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 4 | Completed 4 |
Follow Dosage Forms: new trials by email Literature Review of Dosage Forms trials Research Report on Dosage Forms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) Naltrexone and Bupropion (NB) medication, Placebo - Loss-of-Control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 24 | 2022-06-10 | 2026-08-26 |
| Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) Lisdexamfetamine Dimesylate (Medication), Placebo - Loss-of-control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 16 | 2022-01-02 | 2026-08-06 |
| EXHIT ENTRE Comparative Effectiveness Trial Extended Release Buprenorphine, Treatment as Usual - Substance Use Disorder, Opioid Use Disorder, Moderate | Phase 2 / Phase 3 | Completed | Gavin Bart | 344 | 2021-08-09 | 2025-12-09 |
| World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt debridment - Mucormycosis; Rhinocerebral (Etiology), COVID-19 | Phase 1 / Phase 2 | Completed | Nasser Institute For Research and Treatment | 35 | 2021-05-23 | 2024-02-20 |
| Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus LCLT : 68% elemental L-carnitine and 32 % Tartric acid, Placebo - COVID-19 Virus Infection | Phase 2 | Completed | SENAI CIMATEC | 224 | 2021-03-01 | 2022-07-07 |
| A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers Topical formulation - Androgenetic Alopecia | Phase 2 | Completed | Follicum AB | 209 | 2020-06-24 | 2021-03-01 |
| Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) V184, Placebo - Chikungunya Virus Infection | Phase 2 | Completed | Themis Bioscience GmbH | 41 | 2019-07-16 | 2022-09-08 |
| A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma Cal-1 (LVsh5/C46) drug product - HIV-1 Infection | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 2 | 2019-01-15 | 2025-11-20 |
| Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents Doravirine (DOR), Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF), Antiretroviral (ARV) medications - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 55 | 2018-07-02 | 2023-02-14 |
| Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis Blinded study medication - Knee Osteoarthritis | Phase 2 | Completed | Johns Hopkins University | 58 | 2017-11-01 | 2024-12-11 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule CYD Dengue Vaccine (5 dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 118 | 2016-07-01 | 2022-03-24 |
| Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule CYD Dengue Vaccine (5-dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 251 | 2016-04-14 | 2022-03-24 |
| Mepolizumab in Nasal Polyposis Mepolizumab, Placebo, Run In Medication - Nasal Polyps | Phase 2 | Completed | GlaxoSmithKline | 109 | 2009-05-12 | 2021-04-12 |
| Magnetic Brain Stimulation for the Treatment of Adult Depression Prefrontal rTMS, Antidepressant Regimen, Sham Stimulation - Depression | Phase 2 / Phase 3 | Completed | Medical University of South Carolina | 190 | 2005-02-01 | 2018-12-28 |
| Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II) paclitaxel coated balloon catheter (device with drug) - Coronary Restenosis | Phase 1 / Phase 2 | Completed | University Hospital, Saarland | 56 | 2004-07-01 | 2006-12-12 |
| Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries paclitaxel coated balloon catheter (device with drug) - Peripheral Arterial Disease | Phase 1 / Phase 2 | Completed | University Hospital, Saarland | 87 | 2004-04-01 | 2010-06-30 |
| Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients clofarabine (IV formulation) - Leukemia, Myelocytic, Acute, Pediatric | Phase 2 | Completed | Genzyme, a Sanofi Company | 40 | 2002-05-01 | 2015-03-05 |
| Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia clofarabine (IV formulation) - Acute Myelogenous Leukemia | Phase 2 | Completed | Genzyme, a Sanofi Company | 40 | 2002-05-01 | 2014-03-19 |
| Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL) clofarabine (IV formulation) - Leukemia, Lymphoblastic, Acute, Pediatric | Phase 2 | Completed | Genzyme, a Sanofi Company | 60 | 2002-05-01 | 2022-05-27 |
COVID-19 (2) · Dengue (2) · Leukemia (2) · Obesity (2) · Overweight (2) · Severe Dengue (2) · Alopecia (1) · Chikungunya Fever (1) · Coronary Restenosis (1) · Depression (1) · HIV Infections (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Mucormycosis (1)
Genzyme, a Sanofi Company (3) · Sanofi Pasteur, a Sanofi Company (2) · University Hospital, Saarland (2) · Yale University (2) · Assistance Publique - Hôpitaux de Paris (1) · Follicum AB (1) · Gavin Bart (1) · GlaxoSmithKline (1) · Johns Hopkins University (1) · Medical University of South Carolina (1) · Nasser Institute For Research and Treatment (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · SENAI CIMATEC (1) · Themis Bioscience GmbH (1)
United States (9) · Germany (3) · Brazil (2) · Puerto Rico (2) · Belgium (1) · Colombia (1) · Egypt (1) · France (1) · Honduras (1) · Mexico (1) · Netherlands (1) · Singapore (1) · South Africa (1) · Thailand (1) · United Kingdom (1)
Ann Melvin, MD, MPH (1) · Bruno Scheller, MD (1) · Carlos Grilo, PhD (1) · Claudia M Campbell, Ph.D. (1) · Gavin Bart, MD,PhD (1) · Jens Ricke, MD (1) · Kelly E Dunn, Ph.D. (1) · Mark S. George, MD (1) · Ulrich Speck, PhD (1)
PMID 15141377, PMID 18536865, PMID 18779447, PMID 20439832, PMID 22440499, PMID 23769413, PMID 30986790, PMID 31464558, PMID 32240634, PMID 32391299, PMID 33626291, PMID 33710614, PMID 39623502, PMID 41481837, PMID 42573020
R01DK126637 (2), 2008 (1), 2015 (1), 5UG1DA040316-05 (1), R01DA042751 (1), R01MH069887 (1)